Shots:
- Novo Nordisk reported that etavopivat met both co-1EPs in the P-III (HIBISCUS) study, reducing vaso-occlusive crises (VOCs) and improving haemoglobin response in sickle cell disease
- The study (n=385, ≥12yrs) evaluated Etavopivat (400mg) vs PBO demonstarting reduced VOCs rates by 27% and delayed time to first VOC (~38.4 vs 20.9 weeks), while 48.7% of patients achieved >1 g/dL haemoglobin increase vs 7.2% with PBO
- Novo Nordisk plans regulatory submission in H2 2026, positioning etavopivat as a potential first-in-class oral therapy for SCD
Ref: Novo Nordisk | Image: Novo Nordisk | Press Release
Related News: Novo Nordisk’s Awiqli Receives the US FDA Approval for Type 2 Diabetes
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
